Effects of lorazepam on brain activity pattern during an anxiety symptom provocation challenge

Journal of Psychopharmacology

Volumn 24, Issue 5, 2010, Pages 701-708

  Schunck, T ^a   Mathis, A ^a   Erb, G ^a   Namer, I J ^a   Demazieres A ^a   Luthringer, R ^a  

^a FORENAP   (France)

Author keywords

Anxiety; Aversive conditioning; Fear; FMRI; Human models; Lorazepam

Indexed keywords

LORAZEPAM; PLACEBO;

ADULT; ANTICIPATORY ANXIETY; ARTICLE; AVERSION; BRAIN FUNCTION; CINGULATE GYRUS; CLINICAL TRIAL; CONDITIONING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FRONTAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HAMILTON ANXIETY SCALE; HUMAN; HUMAN EXPERIMENT; IMAGE PROCESSING; INSULA; LOW DRUG DOSE; MALE; MORNING DOSAGE; NEUROMODULATION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STATE TRAIT ANXIETY INVENTORY; TRANSCUTANEOUS NERVE STIMULATION;

ADOLESCENT; ADULT; ANTI-ANXIETY AGENTS; ANXIETY; ATTENTION; BRAIN; DOUBLE-BLIND METHOD; DRUG EVALUATION; FOURIER ANALYSIS; FUNCTIONAL LATERALITY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LORAZEPAM; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; ORGAN SPECIFICITY; REPRODUCIBILITY OF RESULTS; TRANSCUTANEOUS ELECTRIC NERVE STIMULATION; YOUNG ADULT;

EID: 77952161525     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109104864     Document Type: Article

References (29)

1. Arce, E., Miller, DA, Feinstein, JS, Stein, MB, Paulus, MP (2006) Lorazepam dose-dependently decreases risk-taking related activation in limbic areas. Psychopharmacology 189: 105-116.
2. Bond, A., Lader, M. (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: 24-218.
3. Borsini, F., Podhorna, J., Marazziti, D. (2002) Do animal models of anxiety predict anxiolytic-like effects of antidepressants ? Psychopharmacology 163: 121-141.
4. Boshuisen, ML, Ter Horst, GJ, Paans, AM, Reinders, AA, den Boer, JA (2002) rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. Biol Psychiatry 52: 126-135.
5. Bystritsky, A., Pontillo, D., Powers, M., Sabb, FW, Craske, MG, Bookheimer, SY (2001) Functional MRI changes during panic anticipation and imagery exposure. Neuroreport 12: 3953-3957.
6. Cannistraro, PA, Rauch, SL (2003) Neural circuitry of anxiety: evidence from structural and functional neuroimaging studies. Psychopharmacol Bull 37: 8-25.
7. Chua, P., Krams, M., Toni, I., Passingham, R., Dolan, R. (1999) A functional anatomy of anticipatory anxiety. Neuroimage 9: 563-571.
8. Cloninger, CR (1987) A systematic method for clinical description and classification of personality variants. A proposal. Arch Gen Psychiatry 44: 573-588.
9. Etkin, A., Wager, TD (2007) Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry 164: 1476-1488.
10. Gilles, C., Luthringer, R. (2007) Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs. J Psychopharmacol 21: 272-282.
11. Graeff, FG, Parente, A., Del-Ben, CM, Guimarães, FS (2003) Pharmacology of human experimental anxiety. Braz J Med Biol Res 36: 421-432.
12. Grillon, C. (2002) Startle reactivity and anxiety disorders: aversive conditioning, context, and neurobiology. Biol Psychiatry 52: 958-975.
13. Hamilton, M. (1959) The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55.
14. Hennel, F. (1998) Image-based reduction of artifacts in multishot echo-planar imaging. J Magn Reson 134: 206-213.
15. Jensen, J., McIntosh, AR, Crawley, AP, Mikulis, DJ, Remington, G., Kapur, S. (2003) Direct activation of the ventral striatum in anticipation of aversive stimuli. Neuron 40: 1251-1257.
16. Lader, M., Bruce, M. (1986) States of anxiety and their induction by drugs. Br J Clin Pharmacol 22: 251-261.
17. Lecrubier, Y., Sheehan, DV, Weiller, E., Amorin, P., Bonora, I., Harnet Sheehan, K., et al. (1997) The MINI International Neuropsychiatric Interview (MINI). a short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 12: 224-231. (Pubitemid 27298915) (Pubitemid 27298915) (Pubitemid 27298915)
18. McNair, DM, Frankenthaler, LM, Czerlinsky, T., White, TW, Sasson, S., Fisher, S. (1982) Simulated public speaking as a model of clinical anxiety. Psychopharmacology 77: 7-10.
19. Nitschke, JB, Sarinopoulos, I., Mackiewicz, KL, Schaefer, HS, Davidson, RJ (2006) Functional neuroanatomy of aversion and its anticipation. Neuroimage 29: 106-116.
20. Oldfield, RC (1971) The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9: 97-113.
21. Paulus, MP, Feinstein, JS, Castillo, G., Simmons, AN, Stein, MB (2005) Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch Gen Psychiatry 62: 282-288.
22. Pinheiro, SH, Zangrossi J. r, H, Del-Ben, CM, Graeff, FG (2007) Elevated mazes as animal models of anxiety: effects of serotonergic agents. An Acad Bras Cienc 79: 71-85.
23. Price, LH, Goddard, AW, Barr, LC, Goodman, WK (1995) Pharmacological challenges in anxiety disorders. In: Bloom, FE, Kupfer, DJ (eds). Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, pp. 1311-1323.
24. Prut, L., Belzung, C. (2003) The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 28: 3-33.
25. Rauch, SL, Savage, CR, Alpert, NM, Fischman, AJ, Jenike, MA (1997) The functional neuroanatomy of anxiety: a study of three disorders using positron emission tomography and symptom provocation. Biol Psychiatry 42: 446-452.
26. Schunck, T., Erb, G., Mathis, A., Gilles, C., Namer, IJ, Hode, Y., et al. (2006) Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety. Neuroimage 31: 1197-1208.
27. Schunck, T., Erb, G., Mathis, A., Jacob, N., Gilles, C., Namer, IJ, et al. (2008) Test-retest reliability of a functional MRI anticipatory anxiety paradigm in healthy volunteers. J Magn Reson Imaging 27: 459-468.
28. Siepmann, M., Joraschky, P. (2007) Modelling anxiety in humans for drug development. Curr Neuropharmacol 5: 65-72.
29. Spielberger, CD, Gorsuch, RL, Lushene, R., Vagg, PR, Jacobs, GA (1983) Manual for The State-Trait Anxiety Inventory (Form Y). Palo Alto: Consulting Psychologists Press Inc.